Shares of MaxCyte, Inc. (LON:MXCT - Get Free Report) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 298.81 ($3.88) and traded as low as GBX 273 ($3.54). MaxCyte shares last traded at GBX 279 ($3.62), with a volume of 2,555 shares changing hands.
MaxCyte Price Performance
The company has a current ratio of 14.31, a quick ratio of 14.38 and a debt-to-equity ratio of 8.37. The business's 50-day simple moving average is GBX 298.07 and its two-hundred day simple moving average is GBX 325.72. The firm has a market cap of £297.40 million, a price-to-earnings ratio of -1,092.31 and a beta of 1.13.
Insider Transactions at MaxCyte
In other MaxCyte news, insider Stan Erck sold 47,689 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of GBX 388 ($5.03), for a total transaction of £185,033.32 ($239,960.21). 1.45% of the stock is currently owned by corporate insiders.
About MaxCyte
(
Get Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
See Also
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
